StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Free Report) in a research note published on Wednesday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.
Aethlon Medical Price Performance
NASDAQ AEMD opened at $0.38 on Wednesday. The company has a market cap of $5.21 million, a P/E ratio of -0.08 and a beta of 1.74. The stock has a 50-day moving average of $0.41 and a two-hundred day moving average of $0.60. Aethlon Medical has a 1-year low of $0.24 and a 1-year high of $2.35.
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last released its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.10. During the same period last year, the company earned ($1.30) earnings per share. On average, analysts anticipate that Aethlon Medical will post -1.1 EPS for the current fiscal year.
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- What is the Dogs of the Dow Strategy? Overview and Examples
- Texas Roadhouse Stock Steering for New Highs This Year
- Consumer Staples Stocks, Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- The 3 Best Fintech Stocks to Buy Now
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
